- Home
- ILLR vs LUCD Comparison
ILLR vs LUCD Comparison
Compare ILLR & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.11
Company Overview
Basic Information| Metric | ILLR | LUCD |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.5M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ILLR | LUCD |
|---|---|---|
| Price | $0.76 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | ★ 785.5K | 720.5K |
| Earning Date | 12-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $45,244,000.00 | $4,399,000.00 |
| Revenue This Year | N/A | $12.31 |
| Revenue Next Year | N/A | $152.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.01 |
| 52 Week Low | $0.33 | $0.75 |
| 52 Week High | $3.15 | $1.80 |
Technical Indicators
Market Signals| Indicator | ILLR | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 53.02 |
| Support Level | $0.51 | $1.02 |
| Resistance Level | $0.80 | $1.16 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 92.27 | 69.05 |
Price Performance
Historical Comparison ILLR
LUCD
About ILLR Triller Group Inc.
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.